organization

ANTAROS MEDICAL AB

  • project . 2017 - 2021
    Funder: EC Project Code: 116106
    Overall Budget: 22,641,000 EURFunder Contribution: 12,000,000 EUR
    Open Access mandate for Publications
    Partners: GEHC, MSD, Chalmers University of Technology, PFIZER, Lunds universitet, Bayer AG, TRULY LABS AB, STICHTING KATHOLIEKE UNIVERSITEIT, UNIVERSITAIR MEDISCH CENTRUM GRONINGEN, Novo Nordisk...

    1.Our consortium has broad, deep experience of drug development and imaging biomarker (IB) validation. We are internationally recognized experts in transporter biology, animal models of lung injury, toxicology, DCEMRI, compartmental modeling, 1H&129Xe lung MR, and label...

  • project . 2019 - 2024
    Funder: EC Project Code: 831514
    Overall Budget: 27,200,800 EURFunder Contribution: 15,000,000 EUR
    Open Access mandate for Publications
    Partners: TPIZ, Lawrencium Legal, PFIZER, WWU, CEA, Imaginab Inc, Novartis Pharma AG, VLAAMS INSTITUUT BIOTECHNOLOGIE FLANDERS INSTITUTE FOR BIOTECHNOLOGY, FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE, JANSSEN PHARMACEUTICA NV...

    Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unmet need for a person...

  • project . 2016 - 2021
    Funder: EC Project Code: 115974
    Overall Budget: 30,297,900 EURFunder Contribution: 15,085,900 EUR
    Open Access mandate for Publications
    Partners: University of Exeter, University of Sheffield, UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN, HELSINGIN YLIOPISTO, University of Leeds, UKLFR, CHU Bordeaux, UKE, UNIVERSITAIR MEDISCH CENTRUM GRONINGEN, SANOFI-AVENTIS DEUTSCHLAND GMBH...

    Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence have reached epidemic dimensions in recent years. Unfortunately, there are no effective means to prevent or cure DKD, the few existing treatment...

  • project . 2017 - 2022
    Funder: EC Project Code: 777377
    Overall Budget: 47,281,400 EURFunder Contribution: 15,797,900 EUR
    Open Access mandate for Publications
    Partners: EUROPAISCHE VEREINIGUNG FUR LEBERFORSCHUNG EASL, UB, THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE, NKUA, UKA, UMIL, BMS, KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT, ECHOSENS, GENFIT...

    Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient va...

Any information missing or wrong?Report an Issue